Inhibikase Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
This unaudited Form 10-Q covers the three months ended March 31, 2022. Inhibikase is a clinical-stage pharmaceutical company developing oral kinase inhibitors for Parkinson’s disease, related disorders, and oncology.
- Lead candidate IkT-148009 was being evaluated in Phase 1b Parkinson’s disease studies; one eight-patient cohort had completed the study.
- The company planned to initiate Parkinson’s disease Phase 2 studies in the second quarter of 2022, subject to FDA discussions.
- Management also planned potential Multiple System Atrophy studies and an IND submission for oncology candidate IkT-001Pro in the second quarter of 2022.
Financial Results and Key Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Grant revenue | $46,031 | $1,407,165 | Down $1,361,134, or 96.7% |
| Research and development expense | $3,016,991 | $2,431,860 | Up 24.1% |
| Selling, general and administrative expense | $1,669,636 | $1,600,576 | Up 4.3% |
| Loss from operations | $(4,640,596) | $(2,625,271) | Loss increased 76.8% |
| Net loss | $(4,640,601) | $(2,637,068) | Loss increased 76.0% |
| Net loss per share | $(0.18) | $(0.26) | Improved on higher share count |
| Net cash used in operating activities | $(3,934,197) | $(3,934,220) | Essentially unchanged |
The company has no commercial product revenue. Grant revenue represented substantially all reported revenue, and more than 90% of revenue in both comparable periods came from the U.S. government.
- Cash was $36.6 million at March 31, 2022, compared with $40.8 million at December 31, 2021.
- Working capital was $34.0 million, with current liabilities of $4.4 million.
- Debt was reduced to zero after settlement of the $248,911 CEO note on January 3, 2022.
- Accumulated deficit was $34.5 million at March 31, 2022.
- Cash decreased by $4.1 million during the quarter, including $3.9 million used in operations and $204,769 used in financing activities.
- The filing does not present a conventional gross or operating margin because the company has no product sales and reports grant revenue rather than commercial revenue. Operating expenses substantially exceeded revenue.
Material Changes Versus the Prior Comparable Period
- Grant revenue declined sharply as the company shifted resources toward its Phase 1 clinical program rather than grant-funded research.
- Research and development expense increased $585,131, primarily because non-grant clinical research increased approximately $2.1 million, partly offset by lower grant-related research and lower stock-based compensation.
- SG&A increased $69,060 because of higher headcount, legal, board, investor-relations, consulting, and other operating costs, partly offset by lower stock-based compensation.
- Interest expense fell to $5 from $11,797 following repayment of the CEO note.
- Weighted-average shares increased to 25.2 million from 10.1 million, reflecting prior public offerings and other share issuances. During the quarter, the company issued 21,853 shares upon option exercise and 50,000 shares for consulting services.
Guidance, Outlook, Risks, and Unusual Items
- Management estimated that available working capital would fund normal operations into the third quarter of 2023, but stated that substantial additional funding would be needed thereafter.
- Future financing may include equity, debt, grants, licenses, or collaborations. Additional capital may not be available on acceptable terms and could dilute existing stockholders or impose repayment and covenant obligations.
- The company expects research and development expenses and losses to increase as clinical development advances. It has not generated revenue from product sales and cannot predict when, or whether, commercial revenue will begin.
- Planned development milestones depend on FDA, EMA, and other regulatory discussions, clinical and toxicology results, manufacturing readiness, and successful patient enrollment.
- MSA development depends on favorable animal-model results; if those results are not successful, the proposed Phase 2a study may not proceed.
- COVID-19 could delay enrollment, disrupt clinical-trial participation, compromise trial data, and affect manufacturing or distribution, although no material operational impact was reported for the quarter.
- The Russia-Ukraine conflict and related sanctions could increase market volatility, disrupt capital markets, and make future financing more difficult.
- On April 18, 2022, the company entered a Lexington, Massachusetts office lease running from June 2022 through July 2025, with total stated minimum lease obligations of $447,090.
- The financial statements were prepared on a going-concern basis. No material litigation was reported, and management concluded that disclosure controls were effective at a reasonable assurance level.
Facts Investors Should Verify
- Whether planned Phase 2 Parkinson’s disease activities and the IkT-001Pro IND submission occurred on the anticipated timetable.
- Updated clinical, safety, pharmacokinetic, and efficacy results for IkT-148009, including whether animal-model findings translate to human disease modification.
- The pace of cash use and whether the stated runway remains valid as clinical programs expand.
- Timing, structure, pricing, and potential dilution of any future equity or debt financing.
- Availability and renewal of grant funding, including the $314,228 remaining in U.S. Treasury-held grant accounts as of May 3, 2022.
- Regulatory feedback and the outcome of animal studies supporting the proposed MSA program.
- Expansion of accrued research and development liabilities, which increased to $2.9 million at March 31, 2022 from $2.1 million at year-end 2021.